These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 38317842)

  • 41. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
    Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
    Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
    Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
    Front Immunol; 2022; 13():994259. PubMed ID: 36341373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel single-cell model reveals ferroptosis-associated biomarkers for individualized therapy and prognostic prediction in hepatocellular carcinoma.
    Zhou Q; Tao C; Ge Y; Yuan J; Pan F; Lin X; Wang R
    BMC Biol; 2024 Jun; 22(1):133. PubMed ID: 38853238
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.
    Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W
    Front Immunol; 2023; 14():1204338. PubMed ID: 37680641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of Prognosis and Molecular Mechanism of Ferroptosis in Hepatocellular Carcinoma Based on Bioinformatics Methods.
    Xiong Y; Ouyang Y; Fang K; Sun G; Tu S; Xin W; Wei Y; Xiao W
    Comput Math Methods Med; 2022; 2022():4558782. PubMed ID: 35774297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and experimental validation of a machine learning-based disulfidptosis-related ferroptosis score for hepatocellular carcinoma.
    Zhang C; Xu T; Ji K; Cao S; Ai J; Pan J; Cao Y; Yang Y; Jing L; Sun JH
    Apoptosis; 2024 Feb; 29(1-2):103-120. PubMed ID: 37875647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
    Wang L; Wang L; He P
    Front Genet; 2022; 13():1064432. PubMed ID: 36568383
    [No Abstract]   [Full Text] [Related]  

  • 49. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
    Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
    Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.
    Li C; Cui X; Li Y; Guo D; He S
    Sci Rep; 2023 May; 13(1):8681. PubMed ID: 37248280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing a machine learning-based prognosis and immunotherapeutic response signature in colorectal cancer: insights from ferroptosis, fatty acid dynamics, and the tumor microenvironment.
    Zhu J; Zhang J; Lou Y; Zheng Y; Zheng X; Cen W; Ye L; Zhang Q
    Front Immunol; 2024; 15():1416443. PubMed ID: 39076986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
    Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
    Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
    Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
    Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
    Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
    Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma.
    Xu K; Dai C; Yang J; Xu J; Xia C; Li J; Zhang C; Xu N; Wu T
    Comput Biol Med; 2024 Feb; 169():107930. PubMed ID: 38199215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.
    Deng T; Hu B; Jin C; Tong Y; Zhao J; Shi Z; Zhang T; Deng L; Sun Z; Chen G; Wang Y
    J Cell Mol Med; 2021 Jul; 25(14):6618-6633. PubMed ID: 34085405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.
    Ruan WY; Zhang L; Lei S; Zeng ZR; Yang YS; Cao WP; Hao QY; Lu M; Tian XB; Peng PL
    J Cell Mol Med; 2023 Jul; 27(13):1820-1835. PubMed ID: 37248957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a prognostic disulfidptosis-related gene signature in hepatocellular cancer.
    Zhu J; Wu Y; Ji P; Qi J; Yang X; Pocha C; Tustumi F; Biachi de Castria T
    J Gastrointest Oncol; 2024 Aug; 15(4):1647-1656. PubMed ID: 39279954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.